Arginine Vasopressin

ApprovedSmall molecule

SStanford University

Arginine Vasopressin is one of 117 small molecule programs targeting Social Behavior. It is currently in Approved.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

Social BehaviorActive, not recruiting

Septic ShockActive, not recruiting

Acute Kidney InjuryActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

Acute PainRecruiting

Social BehaviorPreclinical

Active, not recruiting

Septic ShockPhase 2/Phase 3

Active, not recruiting

Acute Kidney InjuryPhase 3

Active, not recruiting

Pulmonary Arterial HypertensionApproved

Active, not recruiting

Acute PainPreclinical

Recruiting

Competition

Competitive Landscape

224 competitors in Septic Shock

#DrugCompanyPhaseTrials

Arginine Vasopressin

SStanford University

Approved

1 2

Primaxin

Pfizer

Preclinical

2 3

Intropin

Pfizer

Preclinical

2 4

Zyvox

Pfizer

Preclinical

1 5

Doribax

Spravato

2 7

Cubicin

BBaxter Healthcare Corporation

Preclinical

1 8

Glucophage

EMD Serono

Preclinical

1 9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Avastin

BBio-Thera Solutions

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Acute Pain

NCT03446456

Q2 2027

Phase 3Recruiting

Acute Kidney Injury

NCT06344442

Clinical

Trials by Indication[1]

Low Birth Weight1 trial

Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants

Completed·—·N/A·NCT01318278·70 enrolled

Acute Kidney Injury1 trial

Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06344442·304 enrolled

Social Behavior1 trial

Effects of Intranasal Oxytocin and Vasopressin on Social Behavior

Unknown status·HHadassah Medical Organization·N/A·NCT01296269·150 enrolled

Pulmonary Arterial Hypertension1 trial

Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension

Completed·SStanford University·Phase 4·NCT05439460·15 enrolled

Cerebral Perfusion1 trial

Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients

Completed·UUniversity of Miami·N/A·NCT00795366·96 enrolled

2 more indications

Septic Shock1 trial

Terlipressin in Septic Shock: Effects on Microcirculation

Completed·UUniversity of Roma La Sapienza·Phase 2/3·NCT00995839·60 enrolled

Acute Pain1 trial

The Influence of Vasopressin on Observational Learning of Placebo Analgesia

Recruiting·UUniversity of Maryland, Baltimore·Preclinical·NCT03446456·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Arginine Vasopressin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Arginine Vasopressin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Arginine Vasopressin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SStanford University

Arginine Vasopressin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Low Birth Weight1 trial

Acute Kidney Injury1 trial

Social Behavior1 trial

Pulmonary Arterial Hypertension1 trial

Cerebral Perfusion1 trial

Septic Shock1 trial

Acute Pain1 trial

References

Drug Info

Quick Facts

Related News